Enzymotec Ltd. Announces Publication Acceptance of Clinical Study Results on Usage of Vayacog(R) in Non-Demented Elderly
10 December 2013 - 12:00AM
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and
marketer of innovative bio-functional lipid ingredients, announced
today the acceptance for future publication of its clinical study
results evaluating the safety and effectiveness of
Vayacog
® usage in non-demented elderly.
The article manuscript titled "Phosphatidylserine containing
omega-3 fatty acids may improve memory abilities in non-demented
elderly with memory complaints: Results from an open-label
extension" was accepted for publication in the peer-reviewed
journal "Dementia and Geriatric Cognitive Disorders." The study was
conducted by Professor Amos Korczyn from Sourasky Medical Center,
Department of Neurology, Tel-Aviv, Israel.
Enzymotec's 15-week study was an extension of a previously
published study in 2010. This extension aimed to evaluate the
effect of Vayacog® (one capsule/day) on cognitive performance of
122 non-demented elderly participants with memory complaints.
Efficacy was assessed using a computerized tool and the Clinical
Global Impression of Change (CGI-C) rating scale.
During the study, a significant improvement (p0.05 > ) in
sustained attention and memory recognition was observed in subjects
switching from placebo to Vayacog® (naïve group). Additionally, a
significant improvement in CGI-C was observed in this group.
"We are very pleased with the results of the study, which
further demonstrated the positive effects of consumption of
Vayacog® for dietary management of early memory
impairment in elderly patients," said Dr. Ariel Katz, President and
Chief Executive Officer of Enzymotec Ltd.
"The results are noteworthy because no drug is available that
can ameliorate cognitive state in normal elderly people complaining
of memory impairment," said Professor Amos Korczyn, the principal
investigator of this study.
Vayacog® is an orally administered prescription
medical food for the clinical dietary management of certain lipid
imbalances associated with early memory impairment.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based
products and solutions. The Company develops, manufactures and
markets innovative bio-functional lipid ingredients, as well as
final products, based on sophisticated processes and
technologies.
Forward Looking Statement
This release may contain forward-looking statements, which
express the current beliefs and expectations of Company management.
Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences the following risks: a high proportion of the
sales of our InFat product is sold to end users by a single company
in China; we rely on our Swedish joint venture partner to
manufacture InFat, and certain matters related to the joint venture
are or, based on communications from our joint venture partner, are
the subject of disagreement; our gross profits may be adversely
affected if we are only able to obtain lower quality krill meal;
our ability to obtain krill may be affected by conservation
regulation or initiatives; we are dependent on a single facility
that houses the majority of our operations; we may not be able to
expand our production or processing capabilities or satisfy growing
demand; our product development cycle is lengthy and uncertain, and
our development or commercialization efforts for our products may
be unsuccessful; we are subject to significant and increasing
government regulations regarding the sale and marketing of our
products; we may not be able to protect our proprietary technology
or prevent its unauthorized use by third parties; we are currently
subject to litigation, and in the future may become subject to
additional litigation, regarding intellectual property rights; and
other factors discussed under the heading "Risk Factors" in the
Company's final prospectus for its initial public offering filed
with the Securities and Exchange Commission on September 30, 2013.
Forward-looking statements in this release are made pursuant to the
safe harbor provisions contained in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
made only as of the date hereof, and the company undertakes no
obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: ICR, LLC
Katie Turner
646-277-1228
Katie.turner@icrinc.com
-or-
John Mills
310-954-1105
John.mills@icrinc.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024